Acta Scientific Nutritional Health (ASNH)(ISSN: 2582-1423)

Review Article Volume 5 Issue 10

A Widespread Acquired Ailment, Nonalcoholic Fatty Liver Disease; Its Approaches Related to Nutritional Therapy

Mujahid Hassan1*, Yasir Shah2, Aisha Tariq3, Zainab Qasim3, Sehrish Jabbar3 and Mushaim Fatima3

1Department of Food Technology, Chulalongkorn University, Bangkok, Thailand
2Food Science and Technology Department, Govt. College University, Faisalabad, Pakistan
3Department of Nutritional Sciences, Govt. College University Faisalabad, Pakistan

*Corresponding Author: Mujahid Hassan, Department of Food Technology, Chulalongkorn University, Bangkok, Thailand.

Received: June 28, 2021; Published: September 168, 2021

Abstract

  NAFLD (non-alcoholic fatty liver disease) is an inherited metabolic disorder characterised by triglyceride buildup in the liver (TGs). The four clinical-pathological categories frequently followed by the NAFLD pathway are non-alcoholic steatosis, steatohepatitis, increasing fibrosis/cirrhosis, and hepatocellular cancer. The prevalence of NAFLD is increased by obesity and insulin resistance. NAFLD is linked to liver disease in both children and adults and is influenced by age, gender, race, and ethnicity. Hyper-caloric diets, especially those high in trans-/saturated fat and cholesterol, as well as fructose-sweetened drinks, seems to enhance visceral adiposity in people of all ages. Reduced calorie intake, increased soy protein and whey consumption, and supplementation of monounsaturated fatty acids, omega-3 fatty acids, and fibre, polyphenolic substances have preventative and therapeutic benefits are the initial steps toward its management. Along with good eating habits, exercise and physical activity that leads to weight loss and a reduction in liver fat buildup are also important. The patient becomes vulnerable to liver transplantation due to poor care (the end stage of NAFLD).

Keywords: Non-alcoholic Steahepatitis; Non-alcoholic Fatty Liver; Fibrosis; Cirrhosis; Type 2 Diabetes; Cardiovascular Diseases; Chronic Kidney Diseases; Nutritional Management; Lifestyle Modifications; Liver Transplant

References

  1. Benedict M and XJWjoh Zhang. “Non-alcoholic fatty liver disease: An expanded review”. World Journal of Hepatology 16 (2017): 715.
  2. Leon-Mimila, P., et al. “Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes”. Diabetes and Metabolism2 (2021): 101183.
  3. Lyall MJ., et al. “Non-alcoholic fatty liver disease (NAFLD) is associated with dynamic changes in DNA hydroxymethylation”. Epigenetics 1-2 (2020): 61-71.
  4. Pacana T and AJJCoicn Sanyal, and m. care. “Vitamin E and non-alcoholic fatty liver disease”. 15.6 (2012): 641.
  5. Damiani G., et al. “Nonalcoholic fatty liver disease prevalence in an Italian cohort of patients with hidradenitis suppurativa: A multi-center retrospective analysis”. World Journal of Hepatology4 (2019): 391.
  6. Chalasani N., et al. “The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases”. Hepatology 1 (2018): 328-357.
  7. Chatrath H., et al. “Dyslipidemia in patients with nonalcoholic fatty liver disease”. in Seminars in liver disease. NIH Public Access (2012).
  8. Brunner KT., et al. “Nonalcoholic fatty liver disease and obesity treatment”. Current Obesity Reports3 (2019): 220-228.
  9. Lavine JE., et al. “Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial”. JAMA 16 (2011): 1659-1668.
  10. Trauner M., et al. “Fatty liver and lipotoxicity”. 1801.3 (2010): 299-310.
  11. Hormoznejad R., et al. “Combined cranberry supplementation and weight loss diet in non-alcoholic fatty liver disease: a double-blind placebo-controlled randomized clinical trial”. 71.8 (2020): 991-1000.
  12. Allen AM., et al. “Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year‐community study”. Hepatology5 (2018): 1726-1736.
  13. Semin GR and ER Smith. “Embodied grounding: Social, cognitive, affective, and neuroscientific approaches”. Cambridge University Press (2008).
  14. Lonardo A., et al. “AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions”. Digestive and Liver Disease5 (2017): 471-483.
  15. Betrapally NS., et al. “Gut microbiome and liver disease”. Translational Research 179 (2017): 49-59.
  16. Jacobs A., et al. “An overview of mouse models of nonalcoholic steatohepatitis: from past to present”. Current Protocols in Mouse Biology2 (2016): 185-200.
  17. Santilli F., et al. “Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrome”. Vascular Pharmacology 72 (2015): 16-24.
  18. Lee J., et al. “GLP-1 receptor agonist and non-alcoholic fatty liver disease”. Diabetes and Metabolism Journal4 (2012): 262.
  19. Kleiner DE and EM Brunt. “Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research”. in Seminars in liver disease. Thieme Medical Publishers (2012).
  20. Sheedfar F., et al. “Increased hepatic CD36 expression with age is associated with enhanced susceptibility to nonalcoholic fatty liver disease”. Aging4 (2014): 281.
  21. Adams LA., et al. “The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies”. Journal of Hepatology1 (2005): 132-138.
  22. Maurice J and PJCm Manousou. “Non-alcoholic fatty liver disease”. Clinical Medicine3 (2018): 245.
  23. Brunt EM., et al. “Nonalcoholic fatty liver disease”. Nature Reviews Disease Primers1 (2015): 1-22.
  24. Stefan, N., et al. “Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies”. The Lancet Diabetes and Endocrinology4 (2019): 313-324.
  25. Berná G and MJLI Romero‐Gomez. “The role of nutrition in non‐alcoholic fatty liver disease: Pathophysiology and management”. Liver International 40 (2020): 102-108.
  26. Ge J., et al. “Nonalcoholic Fatty Liver Disease and Diabetes Mellitus Are Associated With Post–Transjugular Intrahepatic Portosystemic Shunt Renal Dysfunction: An Advancing Liver Therapeutic Approaches Group Study”. Liver Transplantation3 (2021): 329-340.
  27. Nobili V., et al. “Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial”. Archives of Disease in Childhood4 (2011): 350-353.
  28. Han MAT., et al. “Diversity in NAFLD: a review of manifestations of nonalcoholic fatty liver disease in different ethnicities globally”. Journal of Clinical and Translational Hepatology1 (2021): 71.
  29. Alexander M., et al. “Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults”. BMJ 367 (2019).
  30. Ullah R., et al. “Role of nutrition in the pathogenesis and prevention of non-alcoholic fatty liver disease: recent updates”. International Journal of Biological Sciences 2 (2019): 265.
  31. Pickett-Blakely O., et al. “Micronutrients in nonalcoholic fatty liver disease pathogenesis”. 6.4 (2018): 451-462.
  32. Hassan HA., et al. “Prevalence of fatty liver changes on non-contrast enhanced computed tomography and its associated risk factors”. International Journal of Public Health and Clinical Sciences (IJPHCS)4 (2019): 68-78.
  33. Genoveva GJFJoMS. “The Influence of Entrepreneurial Culture on Entrepreneurial Intention Among Business Students”. Firm Journal of Management Studies 1 (2019): 40-56.
  34. Valenzuela R. “Non-Alcoholic Fatty Liver Disease-Molecular Bases, Prevention and Treatment”. (2018).
  35. Antipass A., et al. “Evaluation of liver function tests and risk score assessment to screen patients for significant liver disease prior to bariatric and metabolic surgery”. Obesity Surgery7 (2020): 2840-2843.
  36. Samuel VT and GIJCm Shulman. “Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases”. Cell Metabolism1 (2018): 22-41.
  37. Ryan MC., et al. “The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease”. Journal of Hepatology1 (2013): 138-143.
  38. Dyson J., et al. “Republished: non-alcoholic fatty liver disease: a practical approach to treatment”. Postgraduate Medical Journal1072 (2015): 92-101.
  39. Adams LA., et al. “Nonalcoholic fatty liver disease”. 172.7 (2005): 899-905.

Citation

Citation: Mujahid Hassan., et al. “A Widespread Acquired Ailment, Nonalcoholic Fatty Liver Disease; Its Approaches Related to Nutritional Therapy". Acta Scientific Nutritional Health 5.10 (2021): 36-50.

Copyright

Copyright: © 2021 Mujahid Hassan., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.034

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 15, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US